ArticleScientific reports2026
DHX33 inhibitors induced transcriptional changes for a subset of genes in cancer cells.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RNA helicase DHX33 has been shown to regulate many genes involved in cancer development. Whether or not this depends on its helicase activity remains a question. Two previously developed small molecules, BCD38 and KY386, have been shown to inhibit DHX33 helicase activity in vitro. Of them, KY386 is more potent to inhibit cancer development in vitro and in vivo. In this study, BCD38 and KY386, were both used to evaluate gene transcriptional changes upon DHX33 helicase inhibition. The effect was then compared to that of DHX33 knockdown. What was found was that DHX33 inhibitors caused transcriptional changes for a subset of genes, which recapitulated DHX33 knockdown in human cancer cells, albeit with some discrepancy. DHX33 inhibitors selectively downregulated a subset of genes involved in cancer progression in vitro and in vivo. Our study for the first time reveals that specific targeting DHX33 helicase activity with small molecule inhibitors induced gene transcriptional changes, which mimicked the effect the DHX33 knockdown, implicating that the cellular functions of DHX33 is dependent on its helicase activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.